BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yagi R, Midorikawa Y, Moriguchi M, Nakayama H, Aramaki O, Yamazaki S, Higaki T, Takayama T. Liver resection for recurrent hepatocellular carcinoma to improve survivability: a proposal of indication criteria. Surgery. 2018;163:1250-1256. [PMID: 29452700 DOI: 10.1016/j.surg.2017.12.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Periferakis A, Tsigas G, Periferakis AT, Badarau IA, Scheau AE, Tampa M, Georgescu SR, Didilescu AC, Scheau C, Caruntu C. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2021;2021:1840069. [PMID: 34873567 DOI: 10.1155/2021/1840069] [Reference Citation Analysis]
2 Lee J, Joo I, Lee DH, Jeon SK, Lee JM. Clinical outcomes of patients with a high alpha-fetoprotein level but without evident recurrence on CT or MRI in surveillance after curative-intent treatment for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:597-606. [PMID: 32812065 DOI: 10.1007/s00261-020-02707-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Lee MW, Lim HK. Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future. World J Gastroenterol 2018; 24(46): 5215-5222 [PMID: 30581270 DOI: 10.3748/wjg.v24.i46.5215] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
4 Li J, Huang L, Liu C, Qiu M, Yan J, Yan Y, Wei S. Risk factors and clinical outcomes of extrahepatic recurrence in patients with post-hepatectomy recurrent hepatocellular carcinoma. ANZ J Surg 2021;91:1174-9. [PMID: 33724680 DOI: 10.1111/ans.16737] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Abe H, Midorikawa Y, Higaki T, Yamazaki S, Aramaki O, Nakayama H, Moriguchi M, Kanda T, Moriyama M, Okada M, Nishimaki H, Sugitani M, Tsuji S, Takayama T. Magnetic resonance elastography-based prediction of hepatocellular carcinoma recurrence after curative resection. Surgery 2021;170:167-72. [PMID: 33752906 DOI: 10.1016/j.surg.2021.02.027] [Reference Citation Analysis]
6 Midorikawa Y, Takayama T, Moriguchi M, Yagi R, Yamagishi S, Nakayama H, Aramaki O, Yamazaki S, Tsuji S, Higaki T. Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma. World J Surg. 2020;44:232-240. [PMID: 31605170 DOI: 10.1007/s00268-019-05225-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Tan Y, Ding X, Long H, Ye J, Huang T, Lin Y, Lv M, Xie X, Huang G. Percutaneous ethanol injection enhanced the efficacy of radiofrequency ablation in the treatment of HCC: an insight into the mechanism of ethanol action. Int J Hyperthermia 2021;38:1394-400. [PMID: 34542014 DOI: 10.1080/02656736.2021.1977857] [Reference Citation Analysis]
8 Zhang GP, Yue X, Li SQ. Cathepsin C Interacts with TNF-α/p38 MAPK Signaling Pathway to Promote Proliferation and Metastasis in Hepatocellular Carcinoma. Cancer Res Treat 2020;52:10-23. [PMID: 31048666 DOI: 10.4143/crt.2019.145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
9 Feng Y, Wu H, Huang DQ, Xu C, Zheng H, Maeda M, Zhao X, Wang L, Xiao F, Lv H, Liu T, Qi J, Li J, Zhong N, Wang C, Feng H, Liang B, Ren W, Qin C, Nguyen MH, Zhu Q. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.Eur Radiol. 2020;30:6357-6368. [PMID: 32529568 DOI: 10.1007/s00330-020-06990-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]